Leqvio

Novartis pulls the plug on UK-based cardiovascular study
Novartis pulls the plug on UK-based cardiovascular study
Endpoints
Novartis
clinical trials
Leqvio
UK
Cardiovascular
Flag link:
PCSK9 pipeline shows signs of saturation
PCSK9 pipeline shows signs of saturation
EP Vantage
AstraZeneca
ION449
Ionis Pharmaceuticals
Novartis
Leqvio
PCSK9 inhibitors
Flag link:
Novartis says Leqvio launch will feature a 'modest initial ramp,' but blockbuster potential awaits
Novartis says Leqvio launch will feature a 'modest initial ramp,' but blockbuster potential awaits
Fierce Pharma
Novartis
Leqvio
drug launches
Cardiovascular
Flag link:
JPM 2022: Novartis rewrites the drug launch playbook with Leqvio, and it doesn't plan to stop there, exec says
JPM 2022: Novartis rewrites the drug launch playbook with Leqvio, and it doesn't plan to stop there, exec says
Fierce Pharma
JPMHC 2022
Novartis
Leqvio
drug launches
Regeneron
Amgen
Sanofi
Flag link:
It Was To Be The Cholesterol Drug For The Masses. Novartis Changed That.
It Was To Be The Cholesterol Drug For The Masses. Novartis Changed That.
Forbes
Novartis
inclisiran
Leqvio
cholesterol
Flag link:
Novartis wins FDA approval for new heart drug, but faces uphill sales battle
Novartis wins FDA approval for new heart drug, but faces uphill sales battle
BioPharma Dive
Novartis
FDA
Leqvio
cholesterol
Flag link:
Novartis plans unconventional sales strategy for new heart drug
Novartis plans unconventional sales strategy for new heart drug
Beckers Hospital Review
Novartis
pharma marketing
EHRs
Leqvio
Flag link:
Novartis finalizes deal to make new heart drug widely available in England
Novartis finalizes deal to make new heart drug widely available in England
BioPharma Dive
UK
Novartis
Leqvio
heart disease
cholesterol
Flag link:
Novartis looks to manufacturing investment to drive down cost of siRNA drug
Novartis looks to manufacturing investment to drive down cost of siRNA drug
Biopharma Reporter
Novartis
Leqvio
drug manufacturing
siRNA
inclisiran
Flag link:
Novartis eyes New Year verdict from FDA on delayed Leqvio
Novartis eyes New Year verdict from FDA on delayed Leqvio
Pharmaforum
Novartis
FDA
Leqvio
inclisiran
Flag link:
Novartis to make Leqvio for U.S. in Austria to overcome FDA delay
Novartis to make Leqvio for U.S. in Austria to overcome FDA delay
Reuters
Novartis
Leqvio
inclisiran
drug manufacturing
FDA
Austria
Flag link:
Aducanumab tops 2021’s biggest potential launches
Aducanumab tops 2021’s biggest potential launches
EP Vantage
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
Flag link:
Novartis’s big wager on RNAi approaches the finish line
Novartis’s big wager on RNAi approaches the finish line
EP Vantage
Novartis
RNAi
COVID-19
Leqvio
cholesterol
Flag link: